Immunotherapy with chemotherapy for locally advanced stomach cancer
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old (any gender).
- Your stomach cancer is confirmed as adenocarcinoma by pathology (biopsy/surgery tissue test).
- The cancer has not spread to distant organs, and your surgeons think it can be removed (or might be able to be removed).
- You have an ECOG performance status of 0 or 1, meaning you’re able to care for yourself and do light activity.
- Your tumor test shows PD-L1 CPS is 1 or higher.
- You must have enough heart, liver, kidney, and blood function for treatment, and you can be on stable medications for blood pressure or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy for stomach cancer. The goal is to see if this combination can help shrink tumors and improve outcomes better than chemotherapy alone.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
Hear when a new Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.